featured
Minimal Residual Disease Response–Adapted Therapy in Patients With Newly Diagnosed Multiple Myeloma
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
The Lancet Haematology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Minimal residual disease response-adapted therapy in newly diagnosed multiple myeloma (MASTER): final report of the multicentre, single-arm, phase 2 trial
Lancet Haematol 2023 Sep 27;[EPub Ahead of Print], LJ Costa, S Chhabra, E Medvedova, BR Dholaria, TM Schmidt, KN Godby, R Silbermann, B Dhakal, S Bal, S Giri, A D'Souza, AC Hall, P Hardwick, J Omel, RF Cornell, P Hari, NS CallanderFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.